查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464812

腦血管疾病治療市場：依治療方式、產品類型、疾病類型、最終用戶分類 - 全球預測 2024-2030

Cerebrovascular Diseases Treatment Market by Treatment Modality (Endovascular Procedures, Medical Management, Surgical Intervention), Products (Devices, Drug Medication), Disease Type, End-user - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年腦血管疾病治療市場規模為51.2億美元，預計2024年將達54億美元，2030年將達75.9億美元，複合年成長率為5.76%。

腦血管疾病包括影響大腦及其血管的腦循環的多種疾病。具體而言，它包括中風、短暫性腦缺血發作(TIA)、動脈瘤和血管畸形等疾病。腦血管疾病的治療是多方面的，旨在預防高風險族群發病、解決急性症狀以及控制診斷後的長期影響。根據具體病理、嚴重程度和患者的整體健康狀況，治療方法會有很大差異。特定治療策略的選擇取決於綜合方法，包括患者的病歷、腦血管疾病的類型和嚴重程度以及醫療團隊的專業知識。世界人口老化，更容易患中風和動脈瘤等腦血管疾病，以及神經血管護理醫療費用的不斷上漲，正在推動腦血管疾病治療市場的擴張。然而，新興市場的治療和手術費用高昂以及獲得先進醫療設施的機會有限是阻礙市場擴張的主要因素。醫學進步不斷推動腦血管疾病治療的發展，預計未來將為患者提供更有效和個人化的選擇。

主要市場統計
基準年[2023] 51.2億美元
預測年份 [2024] 54億美元
預測年份 [2030] 75.9億美元
複合年成長率（%） 5.76%

治療方式：越來越多採用微創血管內治療

血管內治療方法是治療腦血管疾病的前沿方法，利用微創技術來治療動脈瘤、動靜脈畸形 (AVM) 和急性缺血性腦中風等病理。此方法主要包括血管成形術、置入術和栓塞術等技術。與傳統手術相比，血管內治療具有獨特的優勢，即恢復時間較短，且併發症的風險較低。醫療管理是腦血管疾病治療的基石，重點是透過藥物介入控制症狀和預防疾病進展。這種治療方法包括使用抗凝血劑和抗血小板藥物來防止血栓形成、使用抗高血壓藥物來控制血壓、在缺血性中風的情況下使用他汀類藥物來降低膽固醇水平，以及組織纖維蛋白溶酶原活化劑。醫療管理旨在最大限度地降低未來腦血管事件的風險，管理相關的危險因素，緩解症狀並改善患者的生活品質。當僅透過血管內治療或藥物治療無法充分治療腦血管疾病時，需要進行手術介入。這種治療方法包括頸動脈內膜切除術 (CEA) 等手術。 CEA 涉及手術移除頸動脈斑塊或手術夾閉或盤繞動脈瘤，以預防頸動脈嚴重狹窄患者中風。儘管這些治療方法比其他治療方法更具侵入性和風險，但它們可以挽救生命，並且對於管理嚴重併發症和死亡高風險的病理至關重要。

最終用戶醫院和外科中心對腦血管疾病治療的需求不斷增加

在門診手術中心，腦血管疾病的治療重點是診斷、管理和後續觀察，而不是侵入性手術。這些中心更適合需要持續治療和監測而無需住院的患者。服務包括服用抗凝血劑和抗血小板藥物等藥物、監測以防止症狀惡化，以及提供生活方式諮詢以支持康復並降低未來腦血管事故的風險。醫院和外科中心對於治療腦血管疾病，特別是急性和重症病例至關重要。這些設施可以進行先進的診斷測試、緊急干預和外科手術，例如頸動脈內膜切除術、置入術和動脈瘤夾閉術。也提供即時術後照護和強化復健服務，以確保患者康復並最大程度地減少長期殘疾。此外，這些中心協調多學科護理，包括神經科、外科醫生和治療師，以解決患者病情的各個方面。儘管實驗室和學術機構不直接參與患者護理，但它們為腦血管疾病新治療方法的開發做出了重要貢獻。這些設施進行基礎和臨床研究，以了解疾病的病理學，從而發現新的治療標靶。此外，他還負責測試新藥物、設備和治療通訊協定的安全性和有效性的臨床試驗。這些研究的結果可能有助於增強現有的治療方法，並提供創新的解決方案來改善患者的治療結果。

區域洞察

美洲腦血管疾病治療市場的特點是醫療基礎設施先進，對中風、動脈瘤等腦血管疾病的認知度較高。美國研發投入活躍，醫藥和醫療設備業者實力雄厚，並獲得政府政策支持。在美國，非侵入性治療和個人化醫療有明顯的趨勢。成長要素包括人口老化、高血壓和糖尿病的流行以及不健康生活習慣的養成。在亞太地區，由於醫療成本上升、人們對中風和其他腦血管疾病的認知不斷提高以及醫療基礎設施的改善，腦血管疾病治療市場正在快速成長。尤其是中國、印度等人口老化嚴重的國家，是重要的市場。負擔得起且易於獲得的治療方法的創新以及政府加強醫療保健系統的舉措預計將推動亞太地區腦血管疾病治療市場的成長。歐洲、中東和非洲地區為腦血管疾病的治療提供了多元化的市場環境，其中歐洲因其研發活動和醫療保健支出而成為重要市場。人口老化和生活方式影響歐洲腦血管疾病的盛行率。由於醫療保健投資的增加和醫療服務的改善，中東和非洲的腦血管疾病治療市場正在擴大。創新治療方法和政府措施對於這些地區的市場擴張至關重要。

FPNV定位矩陣

FPNV定位矩陣對於評估腦血管疾病治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對腦血管疾病治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭力評估及資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.腦血管疾病治療市場的市場規模與預測是多少？

2.在腦血管疾病治療市場的預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.腦血管疾病治療市場的技術趨勢和法規結構是什麼？

4.腦血管疾病治療市場主要供應商的市場佔有率是多少？

5.進入腦血管疾病治療市場的合適型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 提高對腦​​血管疾病的認知以及早期篩檢的重要性
      • 隨著全球人口持續老化，醫療保健費用也增加。
    • 抑制因素
      • 腦血管治療費用高
    • 機會
      • 在神經血管護理方面進行了大量的研究和開發工作
      • 用於治療腦血管疾病的設備的進展
    • 任務
      • 副作用風險和缺乏熟練專業人員的風險
  • 市場區隔分析
    • 治療方法：血管內治療因其微創性而被擴大採用
    • 最終使用者：醫院和外科中心對腦血管疾病治療的需求不斷增加
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章依治療方法分類的腦血管疾病治療市場

  • 血管內手術
  • 醫療管理
  • 手術治療

第7章腦血管疾病治療市場：依產品

  • 裝置
  • 藥物治療

第8章腦血管疾病治療市場：依疾病類型

  • 出血性中風
  • 缺血性中風
  • 短暫性腦缺血發作（TIA）

第9章腦血管疾病治療市場：依最終使用者分類

  • 門診治療中心
  • 醫院和外科中心
  • 研究實驗室和學術機構

第10章 北美、南美腦血管疾病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區腦血管疾病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東、非洲腦血管疾病治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • Serenovus推出中間導管“Seleglide 71”，用於急性缺血性腦中風患者的重組
    • Enzen Biosciences 推出雷珠單抗生物相似藥，用於治療新生血管性老齡化黃斑部病變(AMD)
    • Cooper 和 Inspira 合作擴大新澤西州南部的神經科學護理
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-F97DD5A7D993

[190 Pages Report] The Cerebrovascular Diseases Treatment Market size was estimated at USD 5.12 billion in 2023 and expected to reach USD 5.40 billion in 2024, at a CAGR 5.76% to reach USD 7.59 billion by 2030.

Cerebrovascular diseases encompass a range of conditions that affect the cerebral circulation of the brain and its blood vessels. Most notably, these include diseases such as stroke, transient ischemic attack (TIA), aneurysms, and vascular malformations. Treatment for cerebrovascular diseases is multifaceted, designed to either prevent the onset of these conditions in at-risk individuals or to address acute conditions and manage long-term effects post-diagnosis. Treatment modalities vary widely based on the specific condition, its severity, and the patient's overall health. The selection of specific treatment strategies depends on an integrated approach involving the patient's medical history, the type and severity of the cerebrovascular disease, and the expertise of the healthcare team. The rising aging population globally, which is more susceptible to cerebrovascular diseases such as strokes and aneurysms, and the increasing healthcare expenditures in neurovascular care drive the cerebrovascular diseases treatment market expansion. However, the high cost of treatments and surgeries and limited access to the advanced healthcare facilities in developing regions are key factors hindering the market growth. Advances in medical science continue to evolve the landscape of cerebrovascular disease treatment, promising more effective and personalized options for patients moving forward.

KEY MARKET STATISTICS
Base Year [2023] USD 5.12 billion
Estimated Year [2024] USD 5.40 billion
Forecast Year [2030] USD 7.59 billion
CAGR (%) 5.76%

Treatment Modality: Growing adoption of endovascular procedures owing to their minimally invasive nature

Endovascular procedures represent a forefront approach to treating cerebrovascular diseases, leveraging minimally invasive techniques to address conditions such as aneurysms, arteriovenous malformations (AVMs), and acute ischemic strokes. This modality primarily includes techniques such as angioplasty, stenting, and embolization. Endovascular procedures are particularly advantageous due to their minimized recovery times and lower risk of complications compared to traditional surgery. Medical management is a cornerstone in treating cerebrovascular diseases, focusing on controlling symptoms and preventing disease progression through pharmaceutical interventions. This modality includes the administration of anticoagulants and antiplatelet agents to prevent clot formation, antihypertensive drugs to control blood pressure, and statins to reduce cholesterol levels for conditions such as ischemic stroke, medications including tissue plasminogen activator (tPA) may be used to dissolve the clot causing the stroke if administered within a specific time window after symptom onset. Medical management aims to minimize the risk of future cerebrovascular events, manage associated risk factors, and provide symptomatic relief, improving patients' quality of life. Surgical intervention is utilized in cases where cerebrovascular diseases cannot be adequately managed through endovascular procedures or medical management alone. This treatment modality may involve procedures such as carotid endarterectomy (CEA), where plaque is surgically removed from the carotid artery for preventing stroke in patients with significant carotid artery stenosis or surgical clipping and coiling for aneurysms. Though these interventions are more invasive and carry greater risk than other treatment modalities, they can be life-saving and are critical for managing conditions that pose a high risk of serious complications or death.

End-user: Increasing need for cerebrovascular diseases treatment in hospitals and surgical centers

In ambulatory care centers, treatments for cerebrovascular diseases are primarily focused on diagnosis, management, and follow-up care rather than invasive surgical procedures. These centers provide accessibility for patients requiring ongoing treatment or monitoring without hospital admission. Services include administering medications, such as anticoagulants and antiplatelets, monitoring symptoms to prevent progression, and lifestyle counseling to support rehabilitation and reduce the risk of future cerebrovascular events. Hospitals and surgical centers are critical in treating cerebrovascular diseases, especially acute and severe cases. These facilities can perform advanced diagnostic tests, emergency interventions, and surgical procedures such as carotid endarterectomy, stenting, and aneurysm clipping. Immediate post-operative care and intensive rehabilitation services are also provided to ensure patient recovery and minimize long-term disabilities. Additionally, these centers coordinate multidisciplinary care involving neurologists, surgeons, and therapists to address all aspects of the patient's condition. While not directly involved in patient care, research laboratories, and academic institutes significantly contribute to developing new treatments for cerebrovascular diseases. These establishments conduct fundamental and clinical research to understand the pathophysiology of diseases, leading to the discovery of novel therapeutic targets. Furthermore, they are responsible for the clinical trials that test the safety and efficacy of novel drugs, devices, and treatment protocols. Insights gained from these studies aid in enhancing existing treatment approaches and potentially offer innovative solutions to improve patient outcomes.

Regional Insights

The market for cerebrovascular disease treatment in the Americas is characterized by advanced healthcare infrastructure and a high degree of awareness about cerebrovascular diseases such as stroke and aneurysms. The United States has robust R&D investments, a strong presence of pharmaceutical and medical device companies, and supportive government policies. The American region showcases a trend towards non-invasive procedures and personalized medicine. Growth factors include the aging population, the prevalence of hypertension and diabetes, and the adoption of unhealthy lifestyle habits. The Asia-Pacific region presents a rapidly growing cerebrovascular disease treatment market driven by increasing healthcare expenditure, rising awareness about stroke and other cerebrovascular conditions, and improving healthcare infrastructure. The countries such as China and India are particularly significant markets with large aging populations. Innovations in affordable and accessible treatments and governmental efforts to enhance healthcare systems are expected to propel cerebrovascular disease treatment market growth in the Asia-Pacific region. The EMEA region exhibits a diverse market landscape for cerebrovascular disease treatment, with Europe being a significant market due to its research and development activities and healthcare spending. An aging population and lifestyle factors influence the prevalence of cerebrovascular diseases in Europe. The cerebrovascular diseases treatment market in the Middle East and Africa is expanding, driven by increasing healthcare investments and improving access to care. Innovative treatments and government initiatives are crucial for market expansion in these regions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cerebrovascular Diseases Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cerebrovascular Diseases Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cerebrovascular Diseases Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca, AstraZeneca plc, Bayer AG, BIOGEN INC., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., GE HealthCare Technologies Inc., Genentech, Inc., Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Medtronic plc, Merck & Co., Inc., Penumbra, Inc., Pfizer Inc., Sangamo Therapeutics, Inc., Sanofi SA, Siemens Healthineers AG, Sihuan Pharmaceutical Holdings Group Ltd., Takeda Pharmaceutical Co. Ltd., and United Therapeutics Corp..

Market Segmentation & Coverage

This research report categorizes the Cerebrovascular Diseases Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment Modality
    • Endovascular Procedures
    • Medical Management
    • Surgical Intervention
  • Products
    • Devices
      • Carotid Stents
      • Cerebral Balloon Angioplasty and Stenting Systems
      • Clot Retrieval Devices
      • Coil Embolization Devices
      • Embolic Protection Systems
      • Flow Diverter Devices
      • Intracranial Stents
    • Drug Medication
      • Anticoagulants
      • Antihypertensive Drugs
      • Antiplatelet Drugs
      • Cholesterol-lowering Drugs
      • Thrombolytics
  • Disease Type
    • Hemorrhagic Stroke
    • Ischemic Stroke
    • Transient Ischemic Attack (TIA)
  • End-user
    • Ambulatory Care Centers
    • Hospitals & Surgical Centers
    • Research Laboratories & Academic Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cerebrovascular Diseases Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cerebrovascular Diseases Treatment Market?

3. What are the technology trends and regulatory frameworks in the Cerebrovascular Diseases Treatment Market?

4. What is the market share of the leading vendors in the Cerebrovascular Diseases Treatment Market?

5. Which modes and strategic moves are suitable for entering the Cerebrovascular Diseases Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness regarding cerebrovascular diseases and the importance of early screening
      • 5.1.1.2. The rising aging population globally and the increasing healthcare expenditures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of cerebrovascular treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Substantial R&D initiatives in neurovascular care
      • 5.1.3.2. Advancements in devices used for cerebrovascular disease treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Risk of side effects and lack of skilled professional
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Modality: Growing adoption of endovascular procedures owing to their minimally invasive nature
    • 5.2.2. End-user: Increasing need for cerebrovascular diseases treatment in hospitals and surgical centers
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Cerebrovascular Diseases Treatment Market, by Treatment Modality

  • 6.1. Introduction
  • 6.2. Endovascular Procedures
  • 6.3. Medical Management
  • 6.4. Surgical Intervention

7. Cerebrovascular Diseases Treatment Market, by Products

  • 7.1. Introduction
  • 7.2. Devices
  • 7.3. Drug Medication

8. Cerebrovascular Diseases Treatment Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Hemorrhagic Stroke
  • 8.3. Ischemic Stroke
  • 8.4. Transient Ischemic Attack (TIA)

9. Cerebrovascular Diseases Treatment Market, by End-user

  • 9.1. Introduction
  • 9.2. Ambulatory Care Centers
  • 9.3. Hospitals & Surgical Centers
  • 9.4. Research Laboratories & Academic Institutes

10. Americas Cerebrovascular Diseases Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cerebrovascular Diseases Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cerebrovascular Diseases Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Cerenovus Launched Cereglide 71 Intermediate Catheter for Revascularization in Patients with Acute Ischemic Stroke
    • 13.3.2. Enzene Biosciences Launched Biosimilar to Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration (AMD)
    • 13.3.3. Cooper And Inspira Partner to Expand Neuroscience Care In South Jersey
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CEREBROVASCULAR DISEASES TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CEREBROVASCULAR DISEASES TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. CEREBROVASCULAR DISEASES TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. CEREBROVASCULAR DISEASES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CEREBROVASCULAR DISEASES TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY MEDICAL MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY MEDICAL MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CAROTID STENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CAROTID STENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CEREBRAL BALLOON ANGIOPLASTY AND STENTING SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CEREBRAL BALLOON ANGIOPLASTY AND STENTING SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CLOT RETRIEVAL DEVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CLOT RETRIEVAL DEVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COIL EMBOLIZATION DEVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COIL EMBOLIZATION DEVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY FLOW DIVERTER DEVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY FLOW DIVERTER DEVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY INTRACRANIAL STENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY INTRACRANIAL STENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIHYPERTENSIVE DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TRANSIENT ISCHEMIC ATTACK (TIA), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TRANSIENT ISCHEMIC ATTACK (TIA), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HOSPITALS & SURGICAL CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY HOSPITALS & SURGICAL CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 104. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 115. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 116. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 127. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 128. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 156. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 167. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 168. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 179. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 180. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 191. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 192. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 204. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 215. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 216. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 228. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 239. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 240. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 263. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 264. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 275. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 276. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 281. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 286. THAILAND CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 287. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2023 (USD MILLION)
  • TABLE 288. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY PRODUCTS, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DEVICES, 2024-2030 (USD MILLION)
  • TABLE 293. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 294. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DRUG MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 295. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. VIETNAM CEREBROVASCULAR DISEASES TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. VIETNAM CEREBROVASCULAR DISEAS